Browse Category

NASDAQ:ORIS News 4 November 2025 - 31 December 2025

Oriental Rise (ORIS) stock jumps premarket after Daguan Tea acquisition LOI

Oriental Rise (ORIS) stock jumps premarket after Daguan Tea acquisition LOI

NEW YORK, December 31, 2025, 05:13 ET — Premarket Shares of Oriental Rise Holdings Limited jumped 36.9% to $1.67 in premarket trading on Wednesday after the China-based tea supplier said it signed a non-binding letter of intent to acquire a controlling equity interest in Hubei Daguan Tea Industry Group. Public+1 The proposed move matters now because it aims at a pressure point for food-and-beverage producers: securing reliable inputs while controlling costs. Oriental Rise pitched the deal as part of a “vertical integration” strategy—owning more steps of the supply chain, from cultivation and processing to downstream sales—to improve margins over time.
31 December 2025
Oriental Rise’s Wild Tea Ride: From $56 High to Penny Stock – 2025’s Shocking Ups and Downs Revealed

Oriental Rise’s Wild Tea Ride: From $56 High to Penny Stock – 2025’s Shocking Ups and Downs Revealed

Company Overview: A Niche Tea Producer in China Oriental Rise Holdings Limited (ORIS) is an integrated tea products supplier based in Fujian, China. The company cultivates its own tea gardens in Ningde, Fujian, and produces primarily-processed white and black teas as well as refined teasstockanalysis.com. Its vertically integrated operations span from tea leaf cultivation and processing to sales of tea products, serving both wholesale distributors and retail customers across Chinaglobenewswire.comir.mdhtea.cn. This farm-to-cup model sets ORIS apart from many peers that handle only one part of the value chainir.mdhtea.cn. Oriental Rise was founded in 2019 and went public on the Nasdaq
4 November 2025

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop